Daniel Grosslight: Hi. Thanks for taking the question. I want to go back to what’s the – I guess, the topic of the day or maybe top couple years the PPE destocking. Earlier this year, I think you mentioned around your conversations with health systems around a third of hospitals we’re working through their inventories. The third still had access and a third of about a year’s worth of stock. Wondering if you – if there’s been any change to that? And if there’s any way to kind of quantify your conversations with hospitals and their PPE stocks right now?
Alexander Bruni: Yes. All I would say is based on the conversations as well as some of the data we looked at, that has gotten slightly better. And again, we’ve seen that get slightly better from Q1 to Q2. But it’s just – it’s that second bucket of last two thirds, that they have excess stock that’s less than a year up to a year on the other side of it. Those are the ones that it’s slow for those to come down. And again, that’s just one component of it. That’s just what hospitals have. So we’ve seen that improve. But we also have to factor and also we’ve got other channels to the market of our product where those other channels have extra stock. And that’s another one that’s tough to get the arms around as you look at different data like sales tracings to try to get to where you need to get to on that.
Daniel Grosslight: Yes. Yes. Okay. And then on the core distribution ex PPE, it seems like that’s trending nicely around 10% year-over-year growth this year versus mid-single digit last quarter. Just curious what’s causing that acceleration in same-store sales growth?
Alexander Bruni: Yes. I think there’s a couple of things. I think it’s the great service. I was actually with a customer yesterday where we’re running just raw fill rates north between 98% and 99%. So some of the industry-leading raw fill rates. And again, that’s no noise. It’s what they order, they get what they want, when they want. And that’s one of the things that’s driven it. I think the other aspect of it has been some of the new win implementations that are starting to take place. And then just better execution in the field. I think those are three of the major factors that are driving that strong performance in the Medical Distribution division.
Daniel Grosslight: Got it. Thanks for the color.
Operator: We’ll go next to Eric Coldwell at Baird.
Eric Coldwell: Thanks. The last one I touched on my first question. But again, going back to the distribution growth, either the 5% or the 10% ex PPE, it’s pretty good, probably better than market trend in hospitals. I was hoping you could parse that out perhaps differently, what component of that growth is new wins versus penetration of existing accounts? Maybe what kind of offset you had from prior period losses? And then if you could sprinkle in some conversation around volumes and pricing outside of PPE, that would be helpful as well.
Alexander Bruni: Yes. I think at a high level, Eric, and I know we normally haven’t gone into this level of detail, but at a high level, I would think there’s a reasonable blend between price and volume, call it, roughly half price, half volume from a broad standpoint. Again, manufacturers, a lot of times are setting the price with the hospital. We’re passing that out with the cost plus. So it’s roughly about half and half, I would say, if we look at our business. Again, our same-store sales is again, is driving a significant portion of this, which when we use it as a proxy for the health of our business and the health of the industry, when we see 10% same-store sales, excluding PPE, that tells us we’re continuing to expand and gain share, whether that’s both through additional services within the customer, as well as broader portfolio with additional products and penetration with the account.
